Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Abhishek S Kashyap"'
Autor:
Alfred Zippelius, Mélanie Buchi, Richard Klar, Julia Festag, Sven Michel, Frank Jaschinski, Sebastian Kobold, Abhishek S Kashyap, Johannes vom Berg, Laura Fernandez-Rodriguez, Chiara Cianciaruso, Ruben Bill, Marcel P Trefny, Nicole Kirchhammer, Rainer H Kohler, Elham Jones, Andre Maaske, Karen O Dixon, Mikael J Pittet
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 5 (2023)
Background Although immune checkpoint inhibitors have been a breakthrough in clinical oncology, these therapies fail to produce durable responses in a significant fraction of patients. This lack of long-term efficacy may be due to a poor pre-existing
Externí odkaz:
https://doaj.org/article/78cf6c8515374d7f847b8913a986bde6
Autor:
Alfred Zippelius, Petra Herzig, Heinz Läubli, Gieri Cathomas, Christian Klein, Marta Trüb, Franziska Uhlenbrock, Christina Claus, Martin Thelen, Marina Bacac, Maria Amann, Rosemarie Albrecht, Claudia Ferrara-Koller, Daniela Thommen, Sacha Rothschield, Spasenija Savic Prince, Kirsten D Mertz, Robert Rosenberg, Viola Heinzelmann-Schwarz, Mark Wiese, Didier Lardinois, Pablo Umana, Abhishek S Kashyap
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background The costimulatory receptor 4-1BB (CD137, TNFRSF9) plays an important role in sustaining effective T cell immune responses and is investigated as target for cancer therapy. Systemic 4-1BB directed therapies elicit toxicity or low efficacy,
Externí odkaz:
https://doaj.org/article/812e0e185e314e829d4e8fe6aa67b3da
Autor:
Abhishek S. Kashyap, Tamara Thelemann, Richard Klar, Sandra M. Kallert, Julia Festag, Melanie Buchi, Lisa Hinterwimmer, Monika Schell, Sven Michel, Frank Jaschinski, Alfred Zippelius
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Abstract Background Cancer cells are known to develop mechanisms to circumvent effective anti-tumor immunity. The two ectonucleotidases CD39 and CD73 are promising drug targets, as they act in concert to convert extracellular immune-stimulating ATP t
Externí odkaz:
https://doaj.org/article/270e5351314041b4b9b45ed11b5860ce
Autor:
Abhishek S. Kashyap, Laura Fernandez-Rodriguez, Yun Zhao, Gianni Monaco, Marcel P. Trefny, Naohiro Yoshida, Kea Martin, Ashwani Sharma, Natacha Olieric, Pankaj Shah, Michal Stanczak, Nicole Kirchhammer, Sung-Moo Park, Sebastien Wieckowski, Heinz Laubli, Rachid Zagani, Benjamin Kasenda, Michel O. Steinmetz, Hans-Christian Reinecker, Alfred Zippelius
Publikováno v:
Cell Reports, Vol 28, Iss 13, Pp 3367-3380.e8 (2019)
Summary: Dendritic cell (DC) activation is a critical step for anti-tumor T cell responses. Certain chemotherapeutics can influence DC function. Here we demonstrate that chemotherapy capable of microtubule destabilization has direct effects on DC fun
Externí odkaz:
https://doaj.org/article/21a0d97cff3b46a0a90aae9154512253
Autor:
Brett G. Hollier, Zee Upton, Ola Söderberg, David I. Leavesley, Gaëlle Cane, Tristan I. Croll, Manaswini Sivaramakrishnan, Jacqui McGovern, Ali Shokoohmand, Gary K. Shooter, Abhishek S. Kashyap
Supplementary materials and methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19848b031666ecc9752160a367907b61
https://doi.org/10.1158/1535-7163.22508251
https://doi.org/10.1158/1535-7163.22508251
Autor:
Heinz Läubli, Alfred Zippelius, Kirsten D. Mertz, Lukas Flatz, Zlatko Trajanoski, Martin Früh, Frank Stenner, Stefan Schaub, Ilaria Alborelli, Philip Jermann, Spasenija Savic, Florian Geier, Daniela S. Thommen, Severin Poechtrager, Petra Herzig, Monika Kaiser, Abhishek S. Kashyap, Fiamma Berner, Michal A. Stanczak, Benjamin Kasenda, Dietmar Rieder, Franziska Uhlenbrock, Sacha I. Rothschild, Marcel P. Trefny
Supplementary Methods and Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8610d31879e1b10285c161940f55206
https://doi.org/10.1158/1078-0432.22468670
https://doi.org/10.1158/1078-0432.22468670
Autor:
Heinz Läubli, Alfred Zippelius, Kirsten D. Mertz, Lukas Flatz, Zlatko Trajanoski, Martin Früh, Frank Stenner, Stefan Schaub, Ilaria Alborelli, Philip Jermann, Spasenija Savic, Florian Geier, Daniela S. Thommen, Severin Poechtrager, Petra Herzig, Monika Kaiser, Abhishek S. Kashyap, Fiamma Berner, Michal A. Stanczak, Benjamin Kasenda, Dietmar Rieder, Franziska Uhlenbrock, Sacha I. Rothschild, Marcel P. Trefny
Purpose:PD-(L)1–blocking antibodies have clinical activity in metastatic non–small cell lung cancer (NSCLC) and mediate durable tumor remissions. However, the majority of patients are resistant to PD-(L)1 blockade. Understanding mechanisms of pri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ab3d158ae21e7bc8b03fa1743907d49
https://doi.org/10.1158/1078-0432.c.6527030.v1
https://doi.org/10.1158/1078-0432.c.6527030.v1
Autor:
Michal A. Stanczak, Natalia Rodrigues Mantuano, Nicole Kirchhammer, David E. Sanin, Francis Jacob, Ricardo Coelho, Arun V. Everest-Dass, Jinyu Wang, Marcel P. Trefny, Gianni Monaco, Anne Bärenwaldt, Melissa A. Gray, Adam Petrone, Abhishek S. Kashyap, Katharina Glatz, Benjamin Kasenda, Karl Normington, James Broderick, Li Peng, Oliver M.T. Pearce, Erika L. Pearce, Carolyn R. Bertozzi, Alfred Zippelius, Heinz Läubli
Publikováno v:
Science translational medicine : integrating medicine and science / American Association for the Advancement of Science
Immune checkpoint blockade (ICB) has substantially improved the prognosis of patients with cancer, but the majority experiences limited benefit, supporting the need for new therapeutic approaches. Up-regulation of sialic acid–containing glycans, te
Autor:
Laura Fernandez-Rodriguez, Chiara Cianciaruso, Ruben Bill, Marcel P Trefny, Richard Klar, Nicole Kirchhammer, Mélanie Buchi, Julia Festag, Sven Michel, Rainer H Kohler, Elham Jones, Andre Maaske, Abhishek S Kashyap, Frank Jaschinski, Karen O Dixon, Mikael J Pittet, Alfred Zippelius
Publikováno v:
Journal for ImmunoTherapy of Cancer. 11:e006714
BackgroundAlthough immune checkpoint inhibitors have been a breakthrough in clinical oncology, these therapies fail to produce durable responses in a significant fraction of patients. This lack of long-term efficacy may be due to a poor pre-existing
Autor:
Nicole Kirchhammer, Marcel P. Trefny, Marina Natoli, Dominik Brücher, Sheena N. Smith, Franziska Werner, Victoria Koch, David Schreiner, Ewelina Bartoszek, Mélanie Buchi, Markus Schmid, Daniel Breu, K. Patricia Hartmann, Polina Zaytseva, Daniela S. Thommen, Heinz Läubli, Jan P. Böttcher, Michal A. Stanczak, Abhishek S. Kashyap, Andreas Plückthun, Alfred Zippelius
T cell–directed cancer immunotherapy often fails to generate lasting tumor control. Harnessing additional effectors of the immune response against tumors may strengthen the clinical benefit of immunotherapies. Here, we demonstrate that therapeutic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::057aa2b1cc1e6a23fbbeec3ddb22cbba